Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ: MRUS )

47.64 -1.52 (-3.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Albemarle To Rally Around 8%? Here Are 5 Other Price Target Changes For Thursday
Berenberg raised Albemarle Corporation (NYSE: ALB) price target from $260 to $270. Berenberg analyst Andres Castanos Mollor downgraded the stock from Buy to Hold. Albemarle shares fell 7.9% to close at... 
Via Benzinga
Analyst Casts Doubts On Merus' Lung Candidate Safety Profile
Earlier today, Merus N.V. (NASDAQ: MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small... 
Via Benzinga
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Upgrades 
Via Benzinga
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus
Incyte Corporation (NASDAQ: INCY) is  
Via Benzinga
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
Needham Says Merus' ASCO Update On Zeno 'Positive'
Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer. 
Via Benzinga
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings
Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Notable Merus Insider Makes $31M Sale
Mark Lampert, 10% Owner at Merus (NASDAQ:MRUS), made a large insider sell on October 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
45 Biggest Movers From Yesterday
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also rose, gaining 1.22% to 4,416.63. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Merus Stock Flirts With Breakout After Experimental Drug Shrinks All Tumors
Merus is flirting with a buy point on its strong, early-stage cancer test results. 
Via Investor's Business Daily
Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide
Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why Merus Stock Is Flying Higher Today
This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results. 
Via The Motley Fool
Why Are Merus Shares Soaring Thursday?
Merus N.V. (NASDAQ: MRUS) has presented data on MCLA-158 and preclinical data on zenocutuzumab (Zeno) at the AACR-NCI-EORTC Virtual International Conference on... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views
Following the market opening Thursday, the Dow traded up 1.51% to 34,936.37 while the NASDAQ rose 1.56% to 14,728.21. The S&P also rose, gaining 1.45% to 4,426.68. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
58 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021
Upgrades Deutsche Bank upgraded the previous rating for Marriott Vacations Worldwide Corp (NYSE:VAC) from Hold to Buy. Marriott Vacations earned $0.49 in the first quarter... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Wells Fargo boosted the price target for American Express Company (NYSE: AXP) from $165 to $185. American Express shares rose 0.3% to close at $165.00 on Friday. Barclays... 
Via Benzinga
Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers
Eli Lilly & Co’s (NYSE: LLY) R&D partner Merus N.V. (NASDAQ: MRUS) have revealed some new data at ASCO21 for an in-house program,... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
60 Biggest Movers From Yesterday
Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. (NASDAQ: UONE) gained 59.1% to close at $9.56. Urban... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.